{"denoms":[{"counts":[{"groupId":"BG000","value":"21"}],"units":"Participants"}],"groups":[{"description":"Rituximab 375 mg/m2 IV on day 1\\> Cyclophosphamide 300 mg/m2 PO on days 1, 8, 15, 22\\> Bortezomib 1.3 mg/m2 IV on days 1, 8, 15, 22\\> Dexamethasone 40 mg PO on days 1, 8, 15, 22","id":"BG000","title":"Treatment"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"51","upperLimit":"80","value":"69"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}